- Live Vaccines
- Cell free PA Vaccines
Anthrax Vaccine Market size was valued at USD 10.67 billion in 2023 and is poised to reach at USD 11.83 billion in 2030, and is expected to grow at a CAGR of 7.5% from 2024-2030. Anthrax is a severe infectious disease caused by Bacillus anthracis. Signs and symptoms include vomiting, nausea, abdominal pain, headache, loss of appetite, fever, severe bloody diarrhea in the later stages of the disease, sore throat, and difficulty swallowing. Risk factors for anthrax include injection of illegal animal drugs, handling animal skins, and working in veterinary medicine, especially dealing with livestock. The market is driven by the growing threat of communicable diseases such as anthrax across the globe.
Moreover, the cost-effectiveness of immunizations, new funding opportunities from government, donors, and research foundations, and advances in research and manufacturing technologies are expected to drive market revenue growth of the anthrax vaccine over a forecast period. In addition, the availability of large target populations in emerging markets drives the growth of the anthrax vaccine market. However, lack of awareness, the high cost of the vaccine in underdeveloped economies, lack of availability and affordability, and stringent regulations are the factors that are restraining the growth of the market. Anthrax infections are predominantly categorized into cutaneous (95%), pulmonary (5%), and gastrointestinal (1%) origins. Given these risks, anthrax vaccination emerges as a crucial preventive measure to curb the spread of infection. Notably, a study published in NCBI in 2023 highlighted that vaccination campaigns targeting anthrax in both humans and animals have significantly reduced the incidence of the disease in developed countries
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The growing efforts and of interest market players in expanding the product portfolio related to anthrax prevention are expected to impel the market growth over the forecast period. Growing government funding in the United States to generate and store sufficient vaccines against anthrax through various programs, such as Joint Program Executive Office for Chemical and Biological Defense, Biomedical Advanced Research and Development Authority (BARDA), BioShield Legislation and is creating market opportunities for the market players. One of the U.S. FDA-approved products against anthrax is BioThrax, manufactured by Emergent BioDefense Operations Lansing LLC, for active immunization against anthrax.
The Anthrax Vaccine Market is growing at a CAGR of 7.5% over the Forecast Period
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
Emergent BioSolutions , Elusys Therapeutics, Panacea Biotec, Zoetis, Bayer, Colorado Serum Company, Inc, Biogénesis Bago, Emergent BioSolutions, Porton Biopharma Ltd, Merial, Merck, Altimmune, Inc. PharmAthene US Corp, Agrovet, CAVAC, Centro Diagnóstico Veterinario, Ceva Sante Animale
The global anthrax vaccine market is segmented based on vaccine type, end-user, geography
1.Executive Summary |
2.Global Anthrax Vaccine Market Introduction |
2.1.Global Anthrax Vaccine Market - Taxonomy |
2.2.Global Anthrax Vaccine Market - Definitions |
2.2.1.Basis Of Type |
2.2.2.End User |
2.2.3.Region |
3.Global Anthrax Vaccine Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Anthrax Vaccine Market Analysis, 2019-2023 and Forecast 2024-2030 |
4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Anthrax Vaccine Market By Vaccine Type, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
5.1. Live Vaccines |
5.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Cell free PA Vaccines |
5.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
6.Global Anthrax Vaccine Market By End User , 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
6.1. Hospitals |
6.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Clinics |
6.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Vaccination Centers |
6.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Others |
6.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7.Global Anthrax Vaccine Market By Region, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
7.1. North America |
7.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia Pacific (APAC) |
7.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Middle East and Africa (MEA) |
7.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Latin America |
7.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
8.North America Anthrax Vaccine Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
8.1. Basis Of Type Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.1.1.Live Vaccines |
8.1.2.Cell free PA Vaccines |
8.2. End User Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.2.1.Hospitals |
8.2.2.Clinics |
8.2.3.Vaccination Centers |
8.2.4.Others |
8.3. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.3.1.United States of America (USA) |
8.3.2.Canada |
9.Europe Anthrax Vaccine Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
9.1. Basis Of Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Live Vaccines |
9.1.2.Cell free PA Vaccines |
9.2. End User Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Hospitals |
9.2.2.Clinics |
9.2.3.Vaccination Centers |
9.2.4.Others |
9.3. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Germany |
9.3.2.France |
9.3.3.Italy |
9.3.4.United Kingdom (UK) |
9.3.5.Spain |
9.3.6.Rest of EU |
9.3.7. |
10.Asia Pacific (APAC) Anthrax Vaccine Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
10.1. Basis Of Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Live Vaccines |
10.1.2.Cell free PA Vaccines |
10.2. End User Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Hospitals |
10.2.2.Clinics |
10.2.3.Vaccination Centers |
10.2.4.Others |
10.3. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.China |
10.3.2.India |
10.3.3.Australia and New Zealand (ANZ) |
10.3.4.Japan |
10.3.5.Rest of APAC |
11.Middle East and Africa (MEA) Anthrax Vaccine Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
11.1. Basis Of Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Live Vaccines |
11.1.2.Cell free PA Vaccines |
11.2. End User Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Hospitals |
11.2.2.Clinics |
11.2.3.Vaccination Centers |
11.2.4.Others |
11.3. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.GCC Countries |
11.3.2.South Africa |
11.3.3.Rest of MEA |
12.Latin America Anthrax Vaccine Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
12.1. Basis Of Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Live Vaccines |
12.1.2.Cell free PA Vaccines |
12.2. End User Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Hospitals |
12.2.2.Clinics |
12.2.3.Vaccination Centers |
12.2.4.Others |
12.3. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Brazil |
12.3.2.Mexico |
12.3.3.Rest of LA |
13. Competition Landscape |
13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
13.2.1.Emergent BioSolutions , |
13.2.2.Elusys Therapeutics , |
13.2.3.Porton Biopharma Limited , |
13.2.4.Panacea Biotec, |
13.2.5.Zoetis, |
13.2.6.Bayer, |
13.2.7.Emergent BioSolutions, |
13.2.8.Merial, Merck, |
13.2.9.Altimmune, Inc. |
13.2.10.PharmAthene US Corp, |
13.2.11.Agrovet, |
13.2.12.CAVAC, |
14. Research Methodology |
15. Appendix and Abbreviations |